Published by BioScientifica
European Congress of Endocrinology 2006

European Congress of Endocrinology 2006

Glasgow, UK
01 April 2006 - 05 April 2006
European Society of Endocrinology
British Endocrine Societies

Endocrine Abstracts (2006) 11 S64

Gene doping: will the age of gene therapy usher in the age of genetic enhancement?

HL Sweeney

University of Pennsylvania, Philadelphia, United States.


Gene therapy and pharmacological therapies that target gene expression have tremendous potential as novel therapeutic agents. In many cases these agents not only have applications in disease states, but also could have tremendous impact on the physiology of normal individuals. A number of strategies being developed for the treatment of disease have the possibility to eventually be used for genetic enhancement of human performance. For example, genes can be easily transferred into the muscles of laboratory animals using modified viruses, known as adeno-associated virus (AAV). These viruses are now in use in early human clinical trials for genetic diseases. Some of the possible treatments for muscular disorders, which include types of muscular dystrophy, and muscle loss associated with either disuse or aging, could be used in healthy adults to build muscle strength and make muscle more resistant to damage.


Endocrine Abstracts (2006) 11 S64